The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | ESMO WCGIC: highlights in HCC

Name: ESMO WCGIC: highlights in HCC
Uploaded: 2020-07-01T00:00:00Z
Duration: 3 min 33 s
Description: Ghassan Abou-Alfa, MD, of Memorial Sloan-Kettering Cancer Center, New York City, NY, discusses novel treatment approaches in hepatocellular carcinoma (HCC) presented at ESMO WCGIC 2020, and evaluates combination therapies for this indication. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Ghassan Abou-Alfa • 1 Jul 2020

ESMO WCGIC 2020

Gastrointestinal Cancer Liver Cancer Antibodies Atezolizumab Bevacizumab Durvalumab Lenvatinib Nivolumab Pembrolizumab Sorafenib Tremelimumab

Ghassan Abou-Alfa, MD, of Memorial Sloan-Kettering Cancer Center, New York City, NY, discusses novel treatment approaches in hepatocellular carcinoma (HCC) presented at ESMO WCGIC 2020, and evaluates combination therapies for this indication. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).